Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASCO 2023 | Acalabrutinib in combination with bendamustine & rituximab in treatment-naïve or R/R MCL

Tycel Phillips • 4 Jun 2023

ASCO 2023

Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Acalabrutinib Antibodies Bendamustine BTK inhibitors Rituximab

Tycel Phillips, MD, City of Hope, Duarte, CA, discusses the results of a study evaluating the safety and efficacy of acalabrutinib in combination with bendamustine and rituximab (ABR) in patients with treatment-naïve or relapsed/refractory (R/R) mantle cell lymphoma (MCL). This triplet combination was well tolerated and effective, and is being further investigated in Phase III trials. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

An update from ASH 2023: advancements in NHL treatment

Tycel Phillips • 10 Dec 2023

A retrospective analysis of real-world data from patients treated for R/R follicular lymphoma

Tycel Phillips • 10 Dec 2023

Optimal sequencing of CAR-T and bispecifics in NHL

Tycel Phillips • 10 Dec 2023

GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCL

Tycel Phillips • 10 Dec 2023

Related Videos

Employing CAR-T therapies in earlier lines of large B-cell lymphoma treatment

Paolo Cortesi • 24 Apr 2024

The value of axi-cel as a second-line treatment in R/R LBCL

Paolo Cortesi • 24 Apr 2024

Promising therapeutic efficacy of EBV-specific T-cell immunotherapy tabelecleucel in PTLD

Nina Worel • 25 Apr 2024

Investigating production failure and out-of-specification production of CAR T-cell therapeutics

Nina Worel • 25 Apr 2024